Bladder cancer combo therapy trial cut short – what we know
NCT ID NCT03324282
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 2 times
Summary
This phase 2 trial tested whether adding the immunotherapy avelumab to standard chemotherapy (gemcitabine-cisplatin) helps people with advanced bladder cancer that has spread. The study planned to enroll 65 patients but was terminated early. Researchers measured tumor shrinkage and side effects. Because it stopped early, the results are not conclusive, but the data may still offer clues about combining immunotherapy with chemo for this cancer.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
avelumab (immunotherapy) plus gemcitabine-cisplatin (chemotherapy)
What this could lead to
If successful, this combination could improve response rates and delay disease progression for people with advanced bladder cancer.
What could go wrong
The trial was terminated early with only 65 participants, so results are limited. Immunotherapy can cause immune-related side effects, and the added benefit over chemo alone is unproven.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BLADDER CARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
CHU de Besançon
Besançon, France
-
CHU de Bordeaux
Bordeaux, France
-
CHU de Poitiers
Poitiers, France
-
CHU de Strasbourg
Strasbourg, France
-
Centre François Baclesse
Caen, France
-
Centre Léon Bérard
Lyon, France
-
Hôpital Européen Georges-Pompidou, AP-HP
Paris, France
-
Hôpital Saint-Louis, AP-HP
Paris, France
-
Institut Bergonié
Bordeaux, France
-
Institut Gustave Roussy
Villejuif, France
-
Institut Paoli Calmettes
Marseille, France
-
Institut Universitaire du Cancer de Toulouse - Oncopole
Toulouse, France
-
Institut de cancérologie de l'Ouest - René Gauducheau
Nantes, France